ReviewCancer biology & therapy2024
The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response.
Review in Cancer biology & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Single-cell transcriptomic analysis reveals cellular heterogeneity and prognostic subtypes in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Small extracellular vesicles in tumor metabolism and immune escape: biomarkers and therapeutic opportunities.Molecular biology reports · 2026Review
- SNARE proteins as biomarkers and therapeutic targets in central nervous system tumors.Discover oncology · 2026Review
- Colorectal cancer-derived extracellular vesicles: at the crossroads of the tumor microenvironment and gut microbiota.Frontiers in immunology · 2026Review
- LDHA, BIK, and CNIH4 Are Diagnostic Markers of Endoplasmic Reticulum Stress in Lung Cancer Comorbid With Sepsis: Integrating Machine Learning and Single-Cell Analysis of Immune Signaling.Mediators of inflammation · 2026Article
- Orchestrating Tumor Metastasis: Exosomes as Master Regulators of the Local and Distant Microenvironment.International journal of biological sciences · 2026Review
- The role of exosomal PD-L1 in NSCLC immunotherapy.Immunotherapy · 2025Review
- [Research Progress of Neutrophil Extracellular Traps in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.Biomarker research · 2025Review
- Tumor-derived vesicles in immune modulation: focus on signaling pathways.Frontiers in immunology · 2025Review
- Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.Frontiers in medicine · 2025Article
- Fascial Manual Medicine: A Continuous Evolution.Cureus · 2024Review
- Coagulation factor II thrombin receptor as a promising biomarker in breast cancer management.Open life sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays an essential role in tumor cell survival by profoundly influencing their proliferation, metastasis, immune evasion, and resistance to treatment. Extracellular vesicles (EVs) are small particles released by all cell types and often reflect the state of their parental cells and modulate other cells' functions through the various cargo they transport. Tumor-derived small EVs (TDSEVs) can transport specific proteins, nucleic acids and lipids tailored to propagate tumor signals and establish a favorable TME. Thus, the TME's biological characteristics can affect TDSEV heterogeneity, and this interplay can amplify tumor growth, dissemination, and resistance to therapy. This review discusses the interplay between TME and TDSEVs based on their biological characteristics and summarizes strategies for targeting cancer cells. Additionally, it reviews the current issues and challenges in this field to offer fresh insights into comprehending tumor development mechanisms and exploring innovative clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.